Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

NCT02147990 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

318

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor discontinued development of CO-1686 for NSCLC.

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Rociletinib

Sponsor

Clovis Oncology, Inc.